Photo by nci from unsplash
This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ), investigates if amyloid reduction from donanemab treatment is associated with… Click to show full abstract
This post hoc analysis of the randomized clinical trial, Study of LY3002813 in Participants With Early Symptomatic Alzheimer’s Disease (TRAILBLAZER-ALZ), investigates if amyloid reduction from donanemab treatment is associated with slowing of tau pathology and clinical decline in individuals with early symptomatic Alzheimer disease.
Keywords:
reduction donanemab;
donanemab treatment;
amyloid reduction;
pathology;
tau pathology;
pathology clinical
Journal Title: JAMA Neurology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: JAMA Neurology
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!